View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 13, 2022updated 14 Apr 2022 6:21am

Lysogene and Yeda enter gene therapy licencing deal

Lysogene will oversee the preclinical, clinical development, production, regulatory works and marketing of the drug.

Lysogene has exercised its option to sign an exclusive global licence agreement with Yeda Research and Development to develop and market a gene therapy candidate to treat neuronopathic Gaucher disease and Parkinson’s disease (PD) with GBA1 mutations.

Yeda is the Weizmann Institute of Science’s commercial arm.

Lysogene has been partnering with the Weizmann Institute of Science since 2020 to develop a new adeno-associated virus (AAV) gene therapy approach to treat neuronopathic Gaucher disease and PD, as well as various other ailments linked to GBA1 gene mutations. 

The company offered AAV vector design and production expertise while the institute contributed glucocerebrosidase variants with improved biological features. 

Following nearly 20 months of successful partnership, Lysogene opted to exercise its option for licencing the programme based on positive initial biological proof of principle studies.

As per the deal, Lysogene will oversee the preclinical, clinical development, production, regulatory works and marketing of the drug candidate across the globe. 

Yeda is entitled to receive royalty as well as other payments.

Lysogene CSO Ralph Laufer said: “We are thrilled to add to our R&D pipeline a new promising gene therapy asset, which addresses high unmet medical needs in Gaucher disease, as well as broader indications, such as PD-GBA. 

“The cost of these preclinical studies will not affect our cash runway. We continue to replenish our early-stage pipeline to position Lysogene as a key player in the field of gene therapy translational science.”

In August last year, Lysogene initiated dosing of subjects in Phase I/II clinical trial of LYS-GM101 to treat GM1 gangliosidosis in the US.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU